Cuba seeks to establish its own three vaccines in the world market for antigens against covid-19, while accelerating the immunization of its inhabitants starting this month, including children and adolescents.
The first step was the meeting that executives of the national entities that create vaccines have just held here Soberana 02, Soberana Plus and Abdala, and the representative of the World Health Organization and Pan American Health Organization (WHO / PAHO) in the Caribbean country, José Moya.
“The validation process will begin next week and may take weeks or months, but the first step has been taken,” said Moya after the exchange with Dr. Eduardo Martínez, president of the state-owned BioCubaFarma, a drug-producing company, and Vicente Vérez , one of the scientists who created the Sovereign vaccines.
If the procedure is satisfactorily completed, the Cuban vaccines would be inserted into the WHO / PAHO distribution mechanisms.
Martínez announced shortly before the exchange in Havana that “since we have received the authorization for the emergency use of three vaccines against covid-19 by the Cuban regulatory authority, we plan to begin exchanges with the WHO for their recognition.”
Cuba has vaccinated 34 percent of its adult population and remains committed to completing the immunization of all its inhabitants eligible to receive the drug before the end of 2021.
Health authorities failed to have 70 percent of their adult population protected in August, as anticipated, and attributed the breach “to the US blockade that delayed the purchase of components necessary for production.”
Cubans advance in the commercialization of their vaccines
While developing new antigens, Cuba has signed agreements for clinical trials or joint productions with several countries, including Iran and Venezuela, while conversations with other governments advance, taking into account that it is the regulatory authorities of each country that approve or not the use of vaccines.
At the end of August, the Federal Commission for the Protection against Sanitary Risks (Cofepris) issued a favorable opinion on the Cuban vaccine Abdala, the most widely used so far on the island with “highly satisfactory” results, according to scientists.
“This is the step prior to the authorization for the emergency use of the vaccine in Mexico; the next step is the submission of files from the pharmaceutical company Neuronic Mexicana SA de CV, in conjunction with the Cuban Center for Genetic Engineering and Biotechnology, which will be ruled by experts from the Sanitary Authorization Commission, “said Cofepris.
The Cuban entity Cimab SA and Neuronic Mexicana SA de CV announced last Tuesday the creation of the joint venture IncuBIO SA, to produce and develop biotechnology products in Cuba.
Obstacles to Vaccine Validation
“Discrimination in the journals indexed on the findings is a barrier that tends to marginalize the scientific results that generally come from poor countries,” Dr. Vicente Vélez, director of the Finlay Vaccine Institute of Cuba, told Russian television.
Vérez made that statement when commenting on the adventures of scientists from the island to achieve publication in high-ranking specialized journals, generally reproducing reports from the pharmaceutical consortiums that dominate the world market.
The specialist assured that the editors of the most important scientific publications in the world have rejected articles by Cuban experts and then have published issues similar to the signature of authors from other countries.